Comparative Pharmacology
Head-to-head clinical analysis: CRYSELLE versus ENSKYCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CRYSELLE versus ENSKYCE.
CRYSELLE vs ENSKYCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cryselle is a combination oral contraceptive containing ethinyl estradiol and norgestrel. It inhibits ovulation by suppressing gonadotropin release, primarily through estrogenic and progestogenic effects on the hypothalamic-pituitary axis. It also increases cervical mucus viscosity and alters endometrial structure, impeding sperm penetration and implantation.
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
One tablet (0.3 mg norgestrel/0.03 mg ethinyl estradiol) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo.
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
None Documented
None Documented
Terminal elimination half-life approximately 24 hours (range 16-36 h), with clinical significance for once-daily dosing.
12 hours (terminal); allows once-daily dosing in most patients
Renal (50% as metabolites, 20% unchanged), fecal (30%), with enterohepatic recirculation.
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Category C
Category C
Oral Contraceptive
Oral Contraceptive